On October 17, 2024 Breakpoint Therapeutics GmbH ("Breakpoint"), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), reported that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in a poster at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 in Barcelona, Spain (ENA 2024) (Press release, Breakpoint Therapeutics, OCT 17, 2024, View Source [SID1234647244]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DNA polymerase theta is a DNA repair enzyme that is largely absent in normal cells but displays aberrant expression in multiple cancer types which often correlates with poor prognosis. Inhibition of Pol θ is a validated therapeutic modality in certain tumour-specific contexts.
Details of the presentation are as follows:
Abstract Title: Discovery and characterisation of DNA polymerase theta inhibitors for the treatment of cancer
Date: Friday, 25 October, 2024
Time: 9:00 a.m. – 3:00 p.m. CEST
Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
Abstract Number: 339
Poster Board Number: PB327